Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net (loss) income | $(643,417) | $5,117 |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | ||
| Depreciation | 974 | 660 |
| Acquired in-process research and development expense | 697,761 | — |
| Amortization of assembled workforce | 600 | — |
| Inventory obsolescence | 583 | 1,026 |
| Stock-based compensation expense | 30,719 | 42,672 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's D&A?
- BioCryst Pharmaceuticals (BCRX) reported D&A of $513K in Q2 2026.
- How has BioCryst Pharmaceuticals's D&A changed year-over-year?
- BioCryst Pharmaceuticals's D&A increased by 55.9% year-over-year, from $329K to $513K.
- What is the long-term trend for BioCryst Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's D&A has grown at a 15.6% compound annual growth rate (CAGR), from $777K to $1.39M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about BioCryst Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude